HHS declares grounds for emergency use of pain drugs for military casualties

A notice published in the Federal Register on 3 September sets up the legal machinery for emergency use of unapproved pain drugs — or approved drugs used in unapproved ways — in military casualties. The Secretary of Health and Human Services issued it under section 564 of the Federal Food, Drug, and Cosmetic (FD&C) Act, the same authority used for civilian emergency use authorizations [s1].

The declaration is a step, not an authorization of any specific product. It is the predicate that lets the Food and Drug Administration subsequently issue emergency use authorizations (EUAs) for named drugs. Reading the notice carefully is worth doing, because the chain of determinations it recites is unusual.

The chain of determinations

The sequence runs through two officials. On 15 July 2026, according to the notice, the Secretary of War determined under the FD&C Act that there is a military emergency, or a significant potential for a military emergency, involving a heightened risk to U.S. military forces of an attack with a chemical, biological, radiological, or nuclear (CBRN) agent or agents, or an attack by an agent or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to those forces [s1]. (The notice uses the terms "Secretary of War" and "Department of War," abbreviated "DOW.")

The notice states that injuries arising from such attacks may cause forces to experience moderate to severe acute pain and place them at risk of developing life-threatening hemodynamic instability, including shock or respiratory distress [s1].

On the basis of that determination, the Secretary of HHS declared on 31 August 2026 that circumstances exist justifying the authorization of emergency use of drugs identified and supported by the Department of War as addressing an unmet military operations-related medical need — specifically, to manage moderate to severe acute pain in casualties caused by, or associated with, an emergency involving CBRN agents, or agents of military combat, including firearms, projectiles, and explosive devices, that may cause or may otherwise be associated with an imminently life-threatening and specific risk to U.S. military forces [s1].

What this does and does not do

What it does: it satisfies the statutory precondition for EUAs in this category. Under section 564, a declaration by the HHS Secretary that circumstances justify emergency use is what allows FDA to authorize specific products, subject to the terms of any authorization issued [s1].

What it does not do: it names no drug, sets no dose, and authorizes no product on its own. The notice describes an unmet "military operations-related medical need" for acute-pain management identified and supported by the Department of War, but the actual products, their conditions of use, and their labelling would come in later, product-specific authorizations that this notice does not contain [s1].

Why it is worth noting

Section 564 is best known from civilian public-health emergencies, where declarations have covered vaccines, tests and treatments. This declaration applies the same authority to a military context and to a therapeutic category — acute-pain management — rather than to a single pathogen. The predicate is a military-emergency determination about the risk of attack on U.S. forces, not an outbreak.

Two things follow for readers tracking this. First, the substance is still to come: whether any drug is authorized, and on what terms, will be visible only when FDA issues product-level EUAs referencing this declaration. Second, an EUA is by design a lower evidentiary bar than full approval — it turns on whether known and potential benefits outweigh known and potential risks for the declared emergency — so any product authorized under it would carry that caveat, and this is where the safety questions will sit.

It is also worth being precise about what "unmet military operations-related medical need" signals. The notice frames the category around casualties who may face moderate to severe acute pain and a risk of life-threatening hemodynamic instability, including shock or respiratory distress [s1]. That is a battlefield-trauma and mass-casualty framing — the kind of setting where a product not yet fully approved, or an approved product used outside its cleared conditions, might be reached for if the benefit-risk balance in that specific emergency justified it. Whether any such product clears that bar is the question the later, product-level authorizations would have to answer.

This article describes a regulatory declaration and does not offer medical advice. No specific drug is authorized by the notice it summarises.